

BIONIME

Welcome

VIPs

&

Shareholders

To Participate in


Bionime

2023

Investor


Conference

Bionime Corporation
2023 Investor Conference




Introduction to Bionime Corporation

Chairman/ CEO
Roy Hung (黃椿木)



Overseas Subsidiaries



- 6 overseas subsidiaries worldwide
- Products sold in more than 100 countries


Bionime's Products Cover & Connect the 3 Major Medical Devices in the Diabetes Care System

2003
Initial Product
BGM
Blood Glucose Monitor

Bionime started to develop whole new product since 2010, 2016

CGM
Continuous Glucose Monitor

Patch Pump
Disposable Insulin Delivery



- **BGM + CGM + Pump**
  - → account for >80% of diabetes care medical device market value
- **BGM + CGM + Pump**
  - → account for >4.0% of the market value of more than 1,700 global medical products
- Global medical devices annual market value is around US$560 billion/CGAR 5.9%

Bionime integrates 3 major medical devices for blood glucose management with its Rightest Care System, creating a user-centric Diabetes Care Ecosystem

BIONIME

The Soul and Core Spirit of CGM

Time In Range Ratio (TIR)

iFree, Free Your Life!



more than a number!

Clinical Data has shown
If TIR ↑ 10%, A1c will ↓ 0.8%


After 6 months of use, clinical data has shown that **CGM** helps diabetic patients achieve a **1.0% more reduction** in **HbA1c** compared to BGM



Performance that drives outcomes

DIaMonD results published in JAMA demonstrated a 1.0% reduction in mean A1c from baseline with CGM alone










dexcom

Use CGM for 6 months achieves a 1.0% more reduction in HbA1c (compared to traditional BGM)

Reduces the risk of complications by around 15% for diabetic patients


Reduces global medical expenditure by around 1.5% (12% x 80% x 15%)



Control the blood glucose within range (TIR > 70% → HbA1c < 7.0%) as early as possible to avoid complications that causes harms or deaths, and ensure the quality and longevity of life.

Overall,
CGM users can obtain more help in blood glucose management

Lower HbA1c




Clinical Data has shown
TIR increases 10%, A1c decreases 0.8%

Avoid Hypo/ hyperglycemia



Extremely helpful in
reducing the life-threatening risks
for diabetic patients with
unstable blood glucose level
and a tendency to
experience hypoglycemia

Establish a good lifestyle



Understand daily blood glucose changes and
promote behavioral changes
for diabetic patients

IoT-based CGM

Diabetes Care Wisdom System


Data → Information → Knowledge → Wisdom

BGM
(single point measurement)

CGM
(realtime & full-time tracking)


Blood Glucose Data

Data



Glucose Control Information

Information



Professional Knowledge

Knowledge



Life Intelligence

Wisdom

安心控糖，自在生活

糖尿病自我照護
舒適、安心、自在



iFree, Free Your Life!

(Continuous learning & adjustment)

Personalized recommendations for blood glucose management:
diet plan, exercise prescription, health plan...

Bionime Corporation
2023 Operational Overview

ADD Director
Sandy Chen (陳慧真)



Financial report


BIONIME

Unit: thousands of NTD


	2018	2019	2020	2021	2022.H1
Net Revenue	2,172,923	1,668,586	1,849,924	2,210,589	1,265,910
Gross Profit	948,418	749,125	783,131	1,004,126	504,760
Gross Margin(%)	**44%**	**45%**	**42%**	**45%**	**40%**
Operating Expense	792,147	728,004	707,837	872,709	497,280
Operation Profit	156,271	21,121	75,294	131,417	7,480
Operation Margin (%)	**7%**	**1%**	**4%**	**6%**	**1%**
No-operating Items	(21,704)	9,990	(709)	(44,934)	(12,958)
Net income to Parent	106,711	63,520	89,325	91,820	(4,774)
Net Margin(%)	**5%**	**4%**	**5%**	**4%**	**-1%**
EPS **(NT$)**	**1.85**	**1.06**	**1.45**	**1.50**	**(0.09)**

5-year quarterly revenue comparison


- The sales revenue for Q3, 2023, amounted to 425 million NTD, reflecting a decrease of 24.7% compared to the same quarter in 2022.
- The operating performance fell short of expectations primarily due to a reduction in stock by core customers and a shift in user preferences from BGM to CGM.




Sales Region




Product Sales



Product Sales





- Meter: 12%
- Strips: 72%~75%
- Other: 13%~16%

Dividend

BIONIME

Unit: NTD

Item/Year	2018	2019	2020	2021	2022
EPS	2.23	1.85	1.06	1.45	1.50
Cash Dividend	2.0	1.51	0.83	1.25	0.38
Capital reserve	-	0.49	1.17	0.75	1.72
Total	2.0	2.0	2.0	2.0	2.1

BIONIME

iFree 安活

iFree, Free Your Life!



Q&A

Thank you!